ERYTHROMYCIN ETHYLSUCCINATE (erythromycin ethylsuccinate) by ANI Pharmaceuticals is clinical pharmacology orally administered erythromycin ethylsuccinate suspension is readily and reliably absorbed. Approved for the following infections caused by chlamydia trachomatis : conjunctivitis of the newborn, pneumonia of infancy, urogenital infections during pregnancy and 8 more indications. First approved in 1978.
Drug data last refreshed 19h ago
CLINICAL PHARMACOLOGY Orally administered erythromycin ethylsuccinate suspension is readily and reliably absorbed. Comparable serum levels of erythromycin are achieved in the fasting and nonfasting states. Erythromycin diffuses readily into most body fluids. Only low concentrations are normally…
Worked on ERYTHROMYCIN ETHYLSUCCINATE at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.